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Abstract
Background: Decision aids can improve decision making processes, but the amount and type of
information that they should attempt to communicate is controversial. We sought to compare, in
a pilot randomized trial, two colorectal cancer (CRC) screening decision aids that differed in the
number of screening options presented.
Methods: Adults ages 48–75 not currently up to date with screening were recruited from the
community and randomized to view one of two versions of our previously tested CRC screening
decision aid. The first version included five screening options: fecal occult blood test (FOBT),
sigmoidoscopy, a combination of FOBT and sigmoidoscopy, colonoscopy, and barium enema. The
second discussed only the two most frequently selected screening options, FOBT and colonoscopy.
Main outcomes were differences in screening interest and test preferences between groups after
decision aid viewing. Patient test preference was elicited first without any associated out-of-pocket
costs (OPC), and then with the following costs: FOBT-$10, sigmoidoscopy-$50, barium enema-
$50, and colonoscopy-$200.
Results: 62 adults participated: 25 viewed the 5-option decision aid, and 37 viewed the 2-option
version. Mean age was 54 (range 48–72), 58% were women, 71% were White, 24% African-
American; 58% had completed at least a 4-year college degree. Comparing participants that viewed
the 5-option version with participants who viewed the 2-option version, there were no differences
in screening interest after viewing (1.8 vs. 1.9, t-test p = 0.76). Those viewing the 2-option version
were somewhat more likely to choose colonoscopy than those viewing the 5-option version when
no out of pocket costs were assumed (68% vs. 46%, p = 0.11), but not when such costs were
imposed (41% vs. 42%, p = 1.00).
Conclusion: The number of screening options available does not appear to have a large effect on
interest in colorectal cancer screening. The effect of offering differing numbers of options may
affect test choice when out-of-pocket costs are not considered.
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Background
Colon cancer screening is effective in reducing the inci-
dence and mortality from colorectal cancer (CRC), but is
currently underutilized, with national self-reported
screening rates of 57.3% [1]. Several methods of screening
are available and recommended by guideline-issuing
organizations, including fecal occult blood tests, sig-
moidoscopy, colonoscopy, and radiological screening
with barium enema or CT colonography [2]. These tests
differ in several respects, including preparation required,
frequency of screening, amount of discomfort and time
required, chance of complications, out-of-pocket costs,
and efficacy in preventing CRC or death from CRC [3].
Sub-optimal screening rates have led to many efforts to
develop interventions to increase screening. Patient deci-
sion aids have been shown to increase screening rates and
improve decision making for CRC screening [3,4]. Deci-
sion aids help patients become aware of colon cancer as a
salient health issue; provide information about testing
options, including their benefits and downsides; and help
patients to discuss screening with their providers.
One important issue when developing decision aids is the
decision about how much total information to include.
The amount of information that is presented should
reflect moral, ethical, and legal obligations to provide a
balanced and informative tool. Practically, developers
have to balance the benefits of presenting more poten-
tially useful information against the downsides of creating
a tool that is too long and thus impractical or the potential
that providing more information could lead to poorer
decision making processes, as demonstrated by Schwartz
[5] and Iyengar [6]. Two specific challenges in CRC screen-
ing are the questions of how many different testing strate-
gies should be included in the decision aid, and whether
the decision aid should include information about out-of-
pocket costs. In terms of the number of tests, some experts
argue that all plausible testing options should be included
[7,8]. Conversely, the argument for presenting fewer test-
ing options is supported by research that suggests increas-
ing number of choices can result in increased difficulty
with decision making and poor decision outcomes [5,6].
With respect to the issue of costs, two views could be
taken: those who favor inclusion of cost information
could argue that such information is crucial to decision
making because it is important to patients and should be
used to compare the value of screening versus other
important uses; those opposing inclusion could argue that
it is practically difficult to provide information about
costs that is salient on the individual level because of the
differences in insurance coverage in the US.
To help address these issues, we sought to compare, in a
pilot randomized trial, the effect of providing information
about different numbers of CRC screening test options on
interest in screening and screening test preferences, with
and without information about out-of-pocket costs.
Methods
Participant Eligibility
Adults ages 48–75 not currently up-to-date with CRC
screening (FOBT within the last year, sigmoidoscopy or
barium enema in the last 5 years, colonoscopy within the
last 10 years) were recruited to the UNC Decision Support
Lab (DSL) from our DSL participant registry and through
mass media recruiting (newspapers and email listservs).
Individuals with a personal or family history of CRC, pol-
yps, or inflammatory bowel disease were excluded from
the study. This study was reviewed and approved by the
Institutional Review Board at UNC-Chapel Hill.
Eligible patients completed informed consent at the
beginning of their study session. They were randomized
to view one of two decision aids in the lab: a 5-option ver-
sion or a 2-option version. We used the random-number
generator in STATA to create sequential study assignment
envelopes. The envelopes were opened by the research
assistant at the beginning of each participant session and
determined which version of the decision aid participants
viewed.
Decision Aid
The development of the full, 5-option version of the deci-
sion aid has been described previously [3]. The five
screening options included are fecal occult blood test
(FOBT), sigmoidoscopy, a combination of FOBT and sig-
moidoscopy, colonoscopy, and barium enema. The deci-
sion aid contained introductory information about colon
cancer and the screening decision, more detailed informa-
tion about each of the tests, and comparative information
for those who wished to decide between different tests.
Viewing the entire decision aid, which was on DVD,
required approximately 30 minutes. Participants were
required to view the introductory portion of the decision
aid, which lasted approximately 7 minutes, and were able
to view additional information on each test by navigating
the DVD's chapter menu.
The second, 2-option decision aid was a shortened
(approximately 15 minutes total content) version of the
full decision aid that included only the two options, FOBT
and colonoscopy, most frequently chosen by patients in
our previous study [3,4]. The required introductory seg-
ment for this version was approximately 5 minutes. Partic-
ipants could then view additional information on FOBT
and colonoscopy.
The section comparing the different tests in terms of how
often tests need to be completed, preparation for tests,BMC Medical Informatics and Decision Making 2008, 8:4 http://www.biomedcentral.com/1472-6947/8/4
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time required for tests, ability of test to find polyps and
cancer, discomfort during tests, and chance of complica-
tions was included in both versions. Both versions ended
in a stage-based assessment of screening readiness [4].
Measures
The full questionnaires are included as Additional file 1.
Our main outcomes were differences in screening interest
and patient test preferences between versions of the deci-
sion aid. As a pilot study, our sample size was based on
resources available, not a formal power calculation. This
study was conducted as a lab-based study outside of a clin-
ical setting and participants were told to respond to the
best of their ability when indicating a test preference. We
did not measure actual test completion, so test decisions
should be interpreted as hypothetical decisions.
Participants completed questionnaires before and after
viewing the decision aid. For screening interest, we used a
single item with a 5-point Likert response scale that was
assessed pre and post decision aid viewing.
Participant test preferences were also elicited after viewing
the decision aid, first without any associated out-of-
pocket costs, and then with the following costs: FOBT-
$10, sigmoidoscopy-$50, barium enema-$50 and colon-
oscopy-$200. These out-of-pocket cost levels were based,
partially, on estimates of co-payments required in the
Medicare program [9].
We also measured several other secondary outcomes,
including knowledge, decision satisfaction, and deci-
sional conflict. We assessed knowledge using 3 questions
that were administered pre and post decision aid viewing:
1 point was awarded for a correct response, resulting in
scores ranging from 0 – 3. Decision Satisfaction was meas-
ured with a 6 item scale by Wills and Holmes-Rovner [10]
after viewing the decision aid; scores ranged from 6 – 30;
higher scores corresponded to higher satisfaction. O'Con-
nor's 16-item Decisional Conflict Scale [11] was also
assessed after viewing the decision aid. Scores calculated
by adding the total for the responses and dividing by 16,
scores ranged from 1 – 5; lower scores were associated
with lower conflict.
We also assessed several subjective measures of decision
aid content after decision aid viewing, including the
amount of information presented, balance, and overall
impression. These measures also employed Likert
response scales and were drawn from previous studies by
our group [12]. Higher scores were associated with better
subjective impressions of amount of information on
advantages and disadvantages of screening, preparation
for discussion with the doctor, and preparation for mak-
ing a decision. For the subjective balance of the decision
aid we asked: Do you think the video was: strongly in
favor of screening, somewhat in favor of screening, nei-
ther in favor of nor against screening, somewhat against
screening, strongly against screening.
Analysis
We used means and proportions to report our descriptive
statistics. To compare the different versions of the deci-
sion aid, we used t-tests and Wilcoxon rank sum for con-
tinuous measures and chi-square and Fisher's exact tests
for proportions. When the results of the non-parametric
tests did not differ from the parametric ones, we reported
the parametric statistics. Statistical tests were considered
significant with a p-value of 0.05 or less, but results that
did not reach statistically significant were not necessarily
considered clinically unimportant because of our small
sample size. Because our small sample size did not permit
equal distribution of potential confounders, we also per-
formed multivariate analyses, using linear regression and
logistic regression, to account for baseline differences in
the intervention and control groups.
The study was approved by the University of North Caro-
lina Biomedical Institutional Review Board.
Results
We contacted 175 participants from our database, 120
enrolled and 99 completed the study: 25 viewed the 5-
option version, and 37 viewed the 2-option version; 37
others were enrolled in a different arm of the trial that
compared a different decision aid and are not reported
further here (Figure 1). Among the 62 participants, mean
age was 54 (range 48–72), 58% were women, 71% were
White, 24% African-American, 58% had completed at
least a 4-year college degree. Most (58%) had never dis-
cussed CRC screening with their doctor. Most characteris-
tics were relatively well-balanced between groups, except
Study Randomization Figure 1
Study Randomization.BMC Medical Informatics and Decision Making 2008, 8:4 http://www.biomedcentral.com/1472-6947/8/4
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that a greater proportion of women viewed the 5-option
version than the 2-option version. (Table 1)
Effect of number of screening options on screening interest 
and test preferences between groups
When comparing participants that viewed the 5-option
version with participants who viewed the 2-option ver-
sion, there were no differences in interest in screening
after viewing the decision aid (1.8 vs. 1.9, t-test p = 0.76).
Patient preferences for type of screening test, according to
decision aid version viewed, are presented in Table 2. The
proportion of patients choosing colonoscopy over other
test options differed somewhat between those viewing the
5-option version and 2-option version when no out-of-
pocket costs were assumed, although the results did not
reach statistical significance (68% vs. 46%, χ2 p = 0.11).
These differences were not observed when out-of-pocket
costs were imposed (41% vs. 42%, χ2 p = 1.00).
Effect of out-of-pocket costs within groups
The proportion choosing colonoscopy appeared to be
affected by out-of-pocket costs for those viewing the 2-
option version, but not for those viewing the 5-option ver-
sion. For those who viewed the 2-option version, 68% of
participants selected colonoscopy without out-of-pocket
costs, but only 41% selected colonoscopy when out-of-
pocket costs were added. For the 5-option version the pro-
portions were 46% and 42% respectively. (Table 2)
Secondary outcomes between groups
Post-video knowledge scores also did not differ signifi-
cantly (2.1 vs. 2.0, t-test p = 0.75; 36% vs. 32% responding
correctly to all questions) between the two groups. Deci-
sional conflict (mean 1.9 in each group, p = 0.43) and
decision satisfaction (mean 25 in each group, p = 0.78)
were also similar between groups. (Table 3)
For the subjective measures of decision aid content there
were no significant differences between the groups in
regards to the amount of information on advantages (2.9
vs. 2.8, t-test p = 0.41) or disadvantages (2.5 vs. 2.6, t-test
p = 0.49), or in the ability of the decision aid to help pre-
pare people to talk with their doctors (4.2 vs. 3.9, t-test p
= 0.11). There was a significant difference between groups
in the subjective measure of the decision aid's ability to
help people prepare to make a decision with the 5-option
version being rated higher than the 2-option version (4.5
vs. 3.9, t-test p = 0.03).
There was no difference between the groups in the rating
of the videos balance (Fisher's exact p = 0.32). Most rated
the video strongly in favor of screening (5-option version
84% vs. 2-option version 73%) or somewhat in favor of
screening (5-option version 12% vs. 2-option version
19%). Three participants (8%) in the 2-option version
rated the decision aid as neither in favor of nor against
screening.
Multivariate analyses
Because there were differences between the groups at base-
line, we performed multivariate analyses to examine the
effect of individual co-variates (age, sex, educational level,
previous screening discussion) on the relationship
between decision aid version and our outcomes. After
controlling for age, sex, education, and previous screening
discussion, we did not find that any of these variables
affected the (lack of) relationship between decision aid
version and our outcomes seen in bi-variate analyses.
Discussion
The number of screening options presented in a decision
aid does not appear have a large effect on interest in color-
ectal cancer screening. Test choice appeared to differ mod-
estly (although the difference did not reach statistical
significance) between the 5-option and 2-option version
when no out-of-pocket costs were assumed. This differ-
ence was not apparent when participants were asked to
assume modest out-of-pocket costs.
Table 1: Demographic Information
Overall (n = 62) 5-option version (n = 25) 2-option version (n = 37)
Mean age, years (range) 54 55 54
% female 58 68 51
% White 71 68 73
% African-American 24 28 22
% reporting 4 or more years of college 58 60 57
% reporting not having discussed screening with their doctor 58 52 62
Baseline Knowledge Score* 1.6 1.7 1.5
Baseline Screening Interest** 1.9 1.8 1.9
* Mean baseline knowledge scores; range 0–3
** Mean baseline screening interest; range 1–5 with 1 indicated definitely interested in being screened; 2 indicated probably interested in being 
screenedBMC Medical Informatics and Decision Making 2008, 8:4 http://www.biomedcentral.com/1472-6947/8/4
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Those participants viewing the two-test option decision
aid were somewhat more sensitive to out-of-pocket costs
than those viewing the 5-option version, perhaps because
the two tests included, FOBT and colonoscopy, were those
that differed most in terms of potential out-of-pocket
costs. By focusing the decision on these two options, view-
ers may have been drawn to weigh the out-of-pocket costs
more heavily than if they had been exposed to a wider
range of options.
The psychology literature has examined the relationship
between the number of choices offered and its effect on
decision making. Schwartz' [5] reviewed much of this
work and concluded that providing more choices could
lead to poorer decision making processes in both health-
related and non-health-related contexts. Work in con-
sumer psychology by Iyengar [6] and colleagues demon-
strated that the provision of extensive choices led to
dissatisfaction and decision regret which also supports
this premise. Using survey data, Lafata and colleagues
found that patients who reported being offered a choice of
CRC screening modality were less likely to have complete
a CRC screening test in the last 5 years [13].
Based on this work, some cancer screening researchers and
policymakers have questioned the effect of offering
patients more than one option for how to be screened,
suggesting that overall screening rates might be higher if
the patient is only presented with one method. Although
our study did not directly test this question, we did not see
major differences in screening interest between offering
two or five options. Randomized trials from Italy and Aus-
tralia have compared the effect of offering one test versus
choice of FOBT or sigmoidoscopy and did not find impor-
tant differences in screening rates [14,15].
Our findings, with respect to test preferences and the
effect of out-of-pocket costs, are consistent with some of
our previous work as well as work of others [16]. We had
previously shown that out-of-pocket costs affected patient
preferences for CRC screening when considering three
options: FOBT alone, sigmoidoscopy alone, or the combi-
nation of FOBT and sigmoidoscopy [17]. Leard and col-
leagues reported that they did not find cost to be an
important factor in CRC screening decision making, but
they did not compare the effect of providing or not pro-
viding such information [16,18]. Like Leard and col-
leagues, we found that nearly all participants expressed a
preference for some form of screening.
Our study has several limitations. First, it is a small rand-
omized trial. We did not have sufficient power to confirm
Table 2: Preferred test choice without and with out-of-pocket costs
Test Type 5-Option Version (n = 25) 2-Option Version (n = 37)
Without OPC With OPC* Without OPC With OPC**
FOBT 21% 17% 32% 54%
Sigmoidoscopy 4% 8% - -
FOBT & Sigmoidoscopy 21% 21% - -
Colonoscopy 46% 42% 68% 41%
Barium Enema 4% 8% - -
No Screening 4% 4% - 5%
* Proportion of participants choosing colonoscopy with and without out-of-pocket costs for those viewing the 5-option version (p = 0.31 
McNemar's test)
** Proportion of participants choosing colonoscopy based on out-of-pocket costs for the 2-option version (p = 0.0016)
† Proportion participants selecting colonoscopy between groups without out-of-pocket costs (χ2 p = 0.11)
†† Proportion participants selecting colonoscopy between groups with out-of-pocket costs (χ2 p = 1.00)
Table 3: Secondary Outcomes: Knowledge, Decisional Conflict, Decisional Satisfaction and Subjective Measures
5-option version (n = 25) 2-option version (n = 37) p-value
Knowledge 2.1 2.0 0.75
Decisional Conflict 1.9 1.9 0.43
Decisional Satisfaction 25.0 25.0 0.78
Ability to help participate in deciding about screening 4.2 4.0 0.33
Length of Video 3.0 3.0 0.35
Amount of Information on Benefits 2.9 2.8 0.41
Amount of Information on Disadvantages 2.5 2.6 0.49
Ability to help prepare to talk with doctor 4.2 3.9 0.11
Ability to help prepare to make a decision 4.5 3.9 0.03BMC Medical Informatics and Decision Making 2008, 8:4 http://www.biomedcentral.com/1472-6947/8/4
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or exclude modest, but potentially meaningful, differ-
ences in effect. We also did not have a large enough sam-
ple size to ensure equal distribution of potential
confounders, requiring adjustment in multivariate analy-
sis. However, adjusting for these baseline differences did
not change the relationships noted in the bivariate analy-
ses. In addition, we did not assess the amount of informa-
tion that participants viewed beyond the initial required
introduction section of each program. Participants were
reporting their hypothetical interests and preferences for
screening after exposure to a decision aid. The relation-
ship between interest and preferences and actual test
ordering or completion is imperfect. Future studies
should examine the effect of the number of test options
on actual test completion, including whether the "pre-
ferred" test is also the one ordered and completed.
The tests discussed in the decision aid did not include
such newer screening options as fecal immunochemical
tests, stool DNA, or CT colonography, all of which may
have produced different preference patterns. Finally, we
did not randomize the order of questions about prefer-
ences based on inclusion or exclusion of out-of-pocket
costs. It is possible that we would have obtained some-
what different results if we had elicited preferences with
such costs before eliciting them without such costs and
other co-variates.
Conclusion
Based on our results, we conclude that the number of test
options has no major effect on interest in CRC screening.
Future research should consider assessing patient prefer-
ences and assessing individual level change when given
two sets of options (all possible tests or only FOBT and
colonoscopy) to determine whether patients are more or
less likely to get screened. Out-of-pocket costs can have
important effects on test preferences, at least when choices
are constrained to the options of FOBT and colonoscopy.
Insurers and payers should consider the effects of out-of-
pocket costs when developing their screening policies,
particularly if they wish to encourage screening [19-23].
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